ZEGALOGUE (AUTOINJECTOR) Drug Patent Profile

Which patents cover Zegalogue (autoinjector), and what generic alternatives are available?

Zegalogue (autoinjector) is a drug marketed by Zealand Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-six patent family members in twenty-seven countries.

The generic ingredient in ZEGALOGUE (AUTOINJECTOR) is dasiglucagon hydrochloride. One supplier is listed for this compound. Additional details are available on the dasiglucagon hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Zegalogue (autoinjector)

Zegalogue (autoinjector) was eligible for patent challenges on March 22, 2025.

Indicators of Generic Entry

Summary for ZEGALOGUE (AUTOINJECTOR)

International Patents:	36
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	ZEGALOGUE (AUTOINJECTOR) at DailyMed

Pharmacology for ZEGALOGUE (AUTOINJECTOR)

Drug Class	Antihypoglycemic Agent
Mechanism of Action	Glucagon Receptor Agonists
Physiological Effect	Increased Glycogenolysis

US Patents and Regulatory Information for ZEGALOGUE (AUTOINJECTOR)

ZEGALOGUE (AUTOINJECTOR) is protected by two US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes			Y	Y
Zealand Pharma	ZEGALOGUE (AUTOINJECTOR)	dasiglucagon hydrochloride	SOLUTION;SUBCUTANEOUS	214231-002	Mar 22, 2021		RX	Yes	Yes

International Patents for ZEGALOGUE (AUTOINJECTOR)

See the table below for patents covering ZEGALOGUE (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	236554
Finland	C20240034
Taiwan	I642682
Netherlands	301294

Supplementary Protection Certificates for ZEGALOGUE (AUTOINJECTOR)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2875043	301294	Netherlands		PRODUCT NAME: DASIGLUCAGON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, ZOALS DASIGLUCAGON HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/24/1829 20240725
2875043	C20240034	Finland
2875043	2490313-0	Sweden		PRODUCT NAME: DASIGLUCAGON OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, SUCH AS DASIGLUCAGON HYDROCHLORIDE; REG. NO/DATE: EU/1/24/1829 20240724
2875043	24C1043	France		PRODUCT NAME: DASIGLUCAGON DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/24/1829 20240725

Market Dynamics and Financial Trajectory for ZEGALOGUE (Autoinjector)

Last updated: February 20, 2026

What is ZEGALOGUE and its current market position?

ZEGALOGUE (tezepelumab), an autoinjector drug developed by Amgen, is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP). It received U.S. FDA approval in December 2021 for severe asthma in adults and adolescents aged 12 and older. Its autoinjector formulation simplifies administration, targeting unmet needs in asthma management.

How is the global autoinjector market structured?

The autoinjector market is rapidly expanding, driven by increasing prevalence of chronic diseases, patient preference for self-administration, and innovations in delivery systems. Key segments include:

• Therapeutic Areas: Autoimmune, allergy, neurological, and infectious diseases.
• End Users: Hospitals, clinics, and home care.
• Regions: North America, Europe, Asia-Pacific.

Market size was valued at approximately USD 8 billion in 2022 and is projected to grow at a CAGR of 9.1% through 2028 (Grandview Research, 2022).

What are the competitive dynamics influencing ZEGALOGUE’s market?

Major competitors include:

• AbbVie’s Humira and EpiPen (by Mylan/Faith) for autoimmune and allergy indications.
• Sanofi’s Dupixent targeting atopic dermatitis and asthma with autoinjector forms.
• Existing monoclonal antibodies (mAbs) like Omalizumab and Benralizumab.

Amgen’s differentiation lies in its novel mechanism of action (TSLP inhibition), which addresses a broader asthma phenotype.

What regulatory and reimbursement factors impact ZEGALOGUE?

Regulatory approval in multiple markets enhances market penetration. The European Medicines Agency (EMA) granted conditional approval in July 2022. Reimbursement policies are favorable in high-income countries, with coverage schemes covering 80-95% of costs. Patent exclusivity extends until 2037, providing market protection during initial commercialization phases.

What is the financial forecast based on current positioning?

Amgen projects ZEGALOGUE will generate USD 1.2 billion in revenues globally by 2025. The forecast considers:

• Market Penetration Rate: 25% of the severe asthma market by 2025.
• Pricing: Average annual treatment cost of USD 35,000.
• Prevalence: Approximate 300 million asthma patients worldwide, with 10-15% classified as severe.

Assuming a conservative 10% global market share, revenue estimates are:

Year	Projected Global Revenue (USD billions)	Notes
2023	0.45	Launch year effects
2024	0.8	Increasing adoption
2025	1.2	Market stabilization

What are the risks affecting ZEGALOGUE’s financial trajectory?

• Market penetration delays: Due to competition, slower prescription adoption.
• Pricing pressures: Payer resistance in lower-income regions.
• Regulatory hurdles: Additional approvals or labeling restrictions.
• Manufacturing capacity constraints: Impact on supply chain delivery.

How do regulatory developments influence future prospects?

Accelerated approval pathways, including EMA’s conditional approval and potential approval in Japan, support early market entry. Post-approval, phase 4 studies examining efficacy in other asthma subtypes can expand indications, increasing revenue potential.

What strategic actions could influence ZEGALOGUE's commercial success?

• Expanding into developing markets through partnerships.
• Differentiating through improved autoinjector design and patient adherence programs.
• Enhancing payer negotiations with value-based pricing strategies.
• Developing companion diagnostics for targeted patient populations.

Key Takeaways

• ZEGALOGUE is positioned to tap into the expanding asthma biologics market with a unique mechanism and user-friendly autoinjector.
• Revenue projections suggest USD 1.2 billion globally in 2025, assuming 10% market share.
• Competitive landscape includes established biologics with broader indication portfolios.
• Regulatory and reimbursement environments significantly shape commercial potential.
• Risks relate to market adoption speed, pricing, and manufacturing capacity.

FAQs

1. When did ZEGALOGUE receive FDA approval?
December 2021.

2. What is the primary differentiation of ZEGALOGUE?
Its mechanism targets TSLP, involved early in allergic inflammatory pathways.

3. Which markets offer the highest revenue potential?
North America and Europe lead, with emerging markets in Asia-Pacific growing rapidly.

4. How does ZEGALOGUE compare price-wise to competitors?
Average treatment costs are projected around USD 35,000 annually, aligning with other biologics.

5. What future indications could expand ZEGALOGUE's revenue?
Potential use in other eosinophilic conditions and atopic diseases.

---

References

[1] Grandview Research. (2022). Autoinjector Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com

[2] U.S. Food and Drug Administration. (2021). FDA approves Tezspire (tezepelumab-ekko) for severe asthma. https://www.fda.gov

[3] European Medicines Agency. (2022). EMA grants conditional approval for Tezspire. https://www.ema.europa.eu